[Correspondence] Fuzuloparib plus apatinib in BRCA-mutated breast cancer: balancing efficacy and accessibility in regional China – Authors' reply We thank Ziran Qiu and Na Jin for their Correspondence regarding the FABULOUS trial1 and appreciate their practical perspectives. The Lancet Oncology March 2, 2026 Original source
[Correspondence] Fuzuloparib plus apatinib in BRCA-mutated breast cancer: balancing efficacy and accessibility in regional China We congratulate Huiping Li and colleagues on the FABULOUS trial,1 which establishes fuzuloparib, with or without apatinib, as a viable option for HER2-negative metastatic breast cancer with germline BRCA1/2 mutations. As clinicians practising in a prefecture-level hospital in the Hunan province, we consider these findings from the perspective of accessibility and real-world applicability in resource-constrained settings. The Lancet Oncology March 2, 2026 Original source
[Correspondence] AI-assisted screening for pancreatic cancer – Authors' reply We thank Hans Scherübl and Misha D P Luyer1 for their insightful comments on the PANORAMA study,2 regarding the challenges and opportunities of artificial intelligence (AI)-assisted detection of pancreatic ductal adenocarcinoma (PDAC), particularly in early-stage disease. The Lancet Oncology March 2, 2026 Original source
[Correspondence] AI-assisted screening for pancreatic cancer I appreciate the excellent work by Natólia Alves and colleagues,1 comparing artificial intelligence (AI) and radiologists in pancreatic cancer detection using standard of care CT scans (PANORAMA study). The paper is a milestone in evaluating the real-world diagnostic performance of an AI system for the detection of pancreatic ductal adenocarcinoma (PDAC) on contrast-enhanced CT. This important advance will facilitate PDAC… The Lancet Oncology March 2, 2026 Original source
[Comment] Clinical benefit and the Trump administration's cancer medicine reforms In December, 2025, the Trump administration announced completion of the second cycle of historic price negotiations between US Medicare and pharmaceutical manufacturers.1 Concurrently, it released plans to establish international reference pricing to lower the costs of cancer drugs and other medicines in Medicare to levels in peer countries.2 These policy changes could have important effects on access to cancer medicines… The Lancet Oncology March 2, 2026 Original source
[Comment] 20 years of the Stupp protocol: confronting stagnation in glioblastoma therapy 20 years ago, the combination of radiotherapy with concomitant and adjuvant temozolomide, also known as the Stupp protocol,1 transformed glioblastoma treatment. It was the first multimodal regimen to show a survival advantage in newly diagnosed glioblastoma and is the standard of care two decades later. The trial1 identified a biomarker (MGMT) to predict benefit from temozolomide; yet this represents only… The Lancet Oncology March 2, 2026 Original source
[Comment] Stepping through the PORTAL: moving toward personalised management of oligorecurrent prostate cancer Timo F W Soeterik and colleagues1 are to be congratulated for their important contribution to guiding personalised treatment in patients with oligorecurrent prostate cancer, published in The Lancet Oncology. In this multicentre retrospective analysis, the authors curated a cohort of more than 500 men with metachronous oligometastatic prostate cancer who underwent prostate-specific membrane antigen (PSMA) PET for disease characterisation, followed… The Lancet Oncology March 2, 2026 Original source
[Comment] New directions in combination treatment of uveal melanoma with liver metastases Metastatic uveal melanoma is a rare and life-threatening cancer with limited treatment options. A characteristic feature of uveal melanoma is its strong liver tropism, resulting in liver metastases in approximately 90% of patients who develop metastatic disease. This distinct pattern has led to investigations of liver-directed therapeutic strategies in patients with uveal melanoma. The Lancet Oncology March 2, 2026 Original source
[Comment] Towards response-adapted neoadjuvant breast cancer treatment The therapeutic landscape of early-stage HER2-positive breast cancer has been transformed over the past two decades.1 The introduction of HER2-directed therapy, including the antibody trastuzumab, has fundamentally altered the natural history of this disease, converting an aggressive breast cancer subtype associated with poor outcomes into one with high rates of pathological complete response and excellent long-term survival.1,2 These gains were… The Lancet Oncology March 2, 2026 Original source
[Comment] Beyond regional boundaries: crucial gaps in global breast cancer burden estimates The Lancet Oncology Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) study on global breast cancer burden provides comprehensive epidemiological trends from 1990 to 2023, with projections to 2050.1 According to this study, breast cancer was the most diagnosed cancer up until 2023.2 Although this ambitious undertaking addresses crucial needs in global oncology, several methodological concerns warrant attention… The Lancet Oncology March 2, 2026 Original source
[Editorial] England's National Cancer Plan: hollow promises? On Feb 4, 2026—World Cancer Day—the long-overdue National Cancer Plan for England was finally published. The plan sets ambitious targets, promising that three quarters of all patients diagnosed with cancer will survive at least 5 years and that the UK will become a global leader in cancer survival by 2035. However, the feasibility of these ambitions is doubtful. The UK's… The Lancet Oncology March 2, 2026 Original source
Claudin proteins as emerging therapeutic targets for solid tumours <p>Nature Reviews Cancer, Published online: 02 March 2026; <a href="https://www.nature.com/articles/s41568-026-00913-3">doi:10.1038/s41568-026-00913-3</a></p>In this Review, Saviano et al. explore the frequent deregulation of claudins (CLDNs) in solid tumours and highlight their role in cancer progression. They discuss strategies to target CLDNs by exploiting tumour-specific surface expression or inhibiting oncogenic signalling and outline knowledge gaps, challenges and opportunities for advancing CLDN-directed cancer therapies. Nature Reviews Cancer March 2, 2026 Original source
[Policy Review] International Multidisciplinary Consensus Group for Malignant Spinal Cord Compression: recommendations for definitions, reporting items, and study endpoints for clinical trials and audits Malignant spinal cord compression (MSCC) is a serious complication of spinal metastases and primary spinal tumours that can severely affect quality of life and overall survival. Clinical trials have used inconsistent definitions, criteria, and endpoints, limiting comparability. We conducted a Delphi consensus process following a systematic review of prospective MSCC trials from Jan 1, 2003, to Feb 26, 2024. From… The Lancet Oncology February 28, 2026 Original source
[Policy Review] Reirradiation Collaborative Group (ReCOG) consensus on standards for dose evaluation and reporting in patients with multiple courses of radiation therapy: an AAPM/ACRO/ASTRO/CARO/COMP/CADRA/CPQR/ESTRO/NRG-endorsed consensus statement As cancer survivors live longer, technologies improve, and reirradiation (reRT) becomes more common, standardised methods for the assessment and reporting of cumulative radiation doses are needed to allow treatment optimisation and integration with other medical specialties managing these complex patients. This consensus statement, developed by an international collaboration of radiation oncologists, physicists, and other experts in the Reirradiation Collaborative Group,… The Lancet Oncology February 28, 2026 Original source
[Review] Expert recommendations for the conduct and appraisal of qualitative research in oncology Qualitative research is essential in addressing unresolved problems in oncology, yet high-yield strategies to bolster qualitative approaches in cancer research are scarce. To promote the unique strengths of qualitative research and increase uptake in the field of oncology, qualitative methods should show quality and credibility on par with quantitative methods. This Review presents recommendations for applied qualitative cancer research generated… The Lancet Oncology February 28, 2026 Original source
[Review] The power of words: evaluating the role of qualitative methods in cancer research This Review underscores qualitative research as an indispensable facet of scientific inquiry to improve provision of safe, effective, and affordable care for patients with cancer worldwide. Representing a global working group of applied qualitative researchers, our multidisciplinary authorship team defines qualitative research, characterises its purpose and value, and describes specific ways in which qualitative inquiry is central to advancing cures,… The Lancet Oncology February 28, 2026 Original source
[Articles] Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial The significantly improved overall survival and patient-reported measures in CARTITUDE-4 reinforce the use of cilta-cel in treating relapsed or refractory multiple myeloma as early as after first relapse. The Lancet Oncology February 28, 2026 Original source
[Articles] Classification accuracy of a hierarchical molecular inference-based deep-learning system for CNS tumour diagnosis: a multi-institutional, retrospective study Our model provides the basis for a clinically applicable deep-learning assistant to improve human efficiency and accuracy of CNS tumour diagnosis. The model will be made publicly available and could be implemented to assist human pathologists in future prospective studies. The Lancet Oncology February 28, 2026 Original source
[Articles] Inter-rater reliability of CTCAE assessments with or without EORTC patient-reported outcome data in a mixed cancer population: a multinational, open-label, randomised controlled trial Availability of PRO data to providers for CTCAE rating improves the consistency of provider-based symptomatic adverse event detection in patients with cancer. PRO data supports reliable assessment of treatment-related toxicity, highlighting the value of integrating PRO data into clinical evaluations within cancer trials. The Lancet Oncology February 28, 2026 Original source
[Articles] Cabozantinib and temozolomide in patients with unresectable or metastatic leiomyosarcoma and other soft tissue sarcomas: a multicentre, single-arm, lead-in phase 2 trial Cabozantinib with temozolomide showed a meaningful clinical benefit and could potentially be a viable treatment option for patients with unresectable or metastatic leiomyosarcoma. Treatment was tolerable and did not reveal any new safety signals. The Lancet Oncology February 28, 2026 Original source